AstraZeneca Koselugo gets Chinese nod for paediatric patients with neurofibromatosis type 1, plexiform neurofibromas
In addition to China, Koselugo is also approved in the US, EU, Japan and several other countries for the treatment of paediatric patients with NF1 and symptomatic, inoperable PNs.
Marc Dunoyer Li Qingfeng Jiaotong University School Of Medicine National Medical Products Administration Department Of Plastic National Institutes Of Health Cancer Institute
Source: medicaldialogues.in